| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Institutional press release |
| Population | Men |
| Source | Mass General Brigham (EurekAlert! news release) |
| URL | eurekalert.org/news-releases/1127698 (opens in a new tab) |
Specific Claim Evaluated
In a randomized trial of 136 men with testosterone deficiency and undetectable PSA after radical prostatectomy, 12 weeks of testosterone improved sexual activity, desire and physical function compared with placebo, erectile function did not change and no participant had biochemical recurrence.
Primary Research Supporting or Contradicting the Claim
The SPIRIT trial randomized 136 men with low-grade prostate cancer and undetectable PSA for at least 2 years to weekly testosterone cypionate or placebo for 12 weeks; sexual activity improved and no biochemical recurrence occurred, but the trial was not long or large enough to assess clinical recurrence (Bhasin et al., 2026).
Corrected Evidence-Based Interpretation
The release is correct. Findings apply only to men with low-grade disease after prostatectomy and do not establish long-term oncologic safety.
Rationale for Grade
The release reports the null erectile function result and calls for larger, longer studies. Its description of the trial matches the published report.
References
- Bhasin S, Burnett AL, Gagliano-Jucá T, Storer TW, Reid KF, Shang YV, Privat F, Chandra MS, Weiss M, Memish-Beleva Y, Lam H, Kibel AS, Pencina KM. Testosterone treatment in prostate cancer survivors with hypogonadism: a randomized clinical trial. JAMA Intern Med. 2026;186(7):805-814. PMID
Supporting excerpt: "The trial was neither long enough nor large enough to evaluate clinical recurrence"